{"id":33374,"date":"2023-01-30T18:08:34","date_gmt":"2023-01-30T13:08:34","guid":{"rendered":"http:\/\/myanmarnewsgazette.com\/?guid=399addd73877fdfbd06bc444c0e4543d"},"modified":"2023-01-30T18:08:34","modified_gmt":"2023-01-30T13:08:34","slug":"survey-demonstrates-that-individuals-with-copd-seek-more-options-to-reduce-risks-of-seasonal-respiratory-viral-infections","status":"publish","type":"post","link":"https:\/\/myanmarnewsgazette.com\/survey-demonstrates-that-individuals-with-copd-seek-more-options-to-reduce-risks-of-seasonal-respiratory-viral-infections\/","title":{"rendered":"Survey demonstrates that individuals with COPD seek more options to reduce risks of seasonal respiratory viral infections"},"content":{"rendered":"
\n

— ENA Respiratory and COPD Foundation survey confirms patients are overwhelmingly positive about taking an immune-modulating nasal spray to reduce lung disease exacerbations–<\/em><\/p>\n

— Survey was conducted through COPD360Net\u00ae, an innovative COPD Foundation program that identifies unmet patient needs and integrates the patient voice into therapy development–<\/em><\/p>\n

MIAMI and MELBOURNE, Australia, Jan. 30, 2023 (GLOBE NEWSWIRE) — A survey conducted collaboratively by the COPD Foundation, a not-for-profit organization established to improve the lives of people with COPD, bronchiectasis, and nontuberculous mycobacterial (NTM) lung disease, and ENA Respiratory<\/a>, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for the prophylaxis of respiratory viral infections for populations at risk of complications, found patients were overwhelmingly positive about the prospect of taking an antiviral nasal spray throughout the winter season or when at risk for exposure to a respiratory virus to prevent COPD flare-ups. The survey results<\/a> were published in the January issue of the Journal of Patient Experience.<\/em><\/p>\n

The survey was conducted through the COPD Foundation\u2019s COPD360Net\u00ae<\/a> initiative, which facilitates connections between patients with chronic lung diseases, researchers, and other stakeholders to identify unmet patient needs and accelerate new therapy options. The vast majority (>80%) of the 376 patients surveyed expressed interest in a potential new seasonal anti-viral nasal spray, taken either twice weekly during the winter months or for two weeks after exposure to someone with a respiratory illness. Over half (56-58%) of patients with frequent COPD exacerbations were very interested.<\/p>\n

Nearly all patients surveyed say they are vaccinated (>92%) for the flu, pneumonia, and COVID-19 and that they have previously taken antiviral medication during cold and flu season. Even so, more than a third (35%) report that viral illnesses have sometimes resulted in hospitalization and nearly half (45%) have needed antibiotics or steroids to treat complications of a viral illness. About 1 in 8 (12%) say they have been treated in an intensive care unit due to complications of a respiratory illness.<\/p>\n

\u201cThese survey results validate the need for seasonal prophylaxis against respiratory viral infections and the value of INNA-051 for patients at high risk of complications from the flu, colds, COVID-19 and other common respiratory illnesses\u201d said Christophe Demaison, Ph.D., co-founder and CEO of ENA Respiratory.<\/p>\n

\u201cPatient insights are critical to successful therapy development, but too often the patient\u2019s voice isn\u2019t heard. These survey results provide additional evidence that we need more tools in the toolbox to protect people with chronic lung diseases during cold and flu season and prevent flare-ups and complications,\u201d said Ruth Tal-Singer, Ph.D., president of 360Net, COPD Foundation.<\/p>\n

ENA Respiratory and the COPD Foundation launched a partnership in 2022 to develop INNA-051 for people with chronic lung diseases. The partnership added INNA-051 to the COPD Foundation\u2019s COPD360Net\u00ae pipeline and is utilizing its global network of accredited centers, scientific expertise, and patient investigators to optimize and accelerate the clinical development program.<\/p>\n

Recently, ENA Respiratory was awarded a $4.38 million grant from the U.S. Department of Defence to support the development of INNA-051. In a Phase 1 study, INNA-051 was found to be well-tolerated, and the company expects to share Phase 2a results soon.<\/p>\n

Notes to Editors <\/strong><\/p>\n

If you would like to arrange an interview, please contact:<\/p>\n